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Obstructive sleep apnea (OSA) is a multifactorial sleep disorder associated with an
increased risk of cardiovascular mortality and morbidity. Several mechanisms have been
proposed to explain the association between OSA and cardiovascular dysfunction. One of
the proposed mechanisms is an inflammatory response to OSA mediated by tumor necro-
sis factor (TNF-α). Patients with OSA have higher plasma, serum, and intracellular levels
of TNF-α, which may be reduced after apnea treatment with continuous positive airway
pressure (CPAP). BecauseTNF-α plays an important role in OSA related cardiovascular mor-
bidity, the present review aims to identify other preventive measures, in addition to CPAP,
that may minimize the inflammatory process in OSA and consequently the risk of pre-
mature death due to cardiovascular dysfunction. Thus, we hypothesized that a nutritional
immunology profile, i.e., supplementation with omega-3 fatty acids, may be valuable for
individuals with OSA.
Keywords: obstructive sleep apnea, omega-3, cardiovascular, inflammation,TNF-α
Obstructive sleep apnea (OSA), a common form of sleep-
disordered breathing, is a multifactorial sleep disorder associated
with several risk factors, including excess body weight, male gen-
der, older age, neck circumference, body mass index, and high
blood pressure (1, 2). OSA affects up to 32.8% of the popula-
tion (3) and, as demonstrated in the Sleep Heart Health study, is
linked to an increased risk of cardiovascular mortality and mor-
bidity (4). Population-based longitudinal studies have shown that
individuals with severe OSA have a threefold greater risk of all-
cause mortality and a higher cardiovascular mortality at 18-year
follow-up (5–7). In addition, OSA has been independently associ-
ated with specific cardiovascular outcomes such as hypertension
(8), stroke (9, 10), myocardial ischemia (11, 12), and arrhythmias
with an increased risk for sudden cardiac death (13, 14). Sev-
eral mechanisms have been proposed to explain the association
between OSA and cardiovascular dysfunction (15). Interestingly,
the accumulated evidence based on clinical studies as well as ani-
mal models and cell culture indicates that inflammatory cytokines,
especially tumor necrosis factor (TNF, also known as TNF-α), play
an important role in OSA related cardiovascular morbidity (15).
In 1975, TNF-α was identified as an endotoxin induced glyco-
protein that caused hemorrhagic necrosis of sarcomas that had
been transplanted into mice. Human TNF was cloned 10 years
later (16–18). Briefly, TNF-α is an inflammatory cytokine pro-
duced by macrophages/monocytes during acute inflammation and
is responsible for a diverse range of signaling events within cells
that lead to necrosis or apoptosis (19). In addition to its involve-
ment in a diverse range of inflammatory, infectious, and malignant
conditions, the importance of TNF-α has been highlighted by the
efficacy of anti-TNF antibodies or soluble TNF receptors (TNFRs)
in controlling inflammatory conditions (18). Several important
discoveries have been made in elucidating the precise role of TNF-
α in the cardiovascular pathogenesis of OSA. Entzian et al. (20)
demonstrated that the circadian rhythm of TNF-α release was sig-
nificantly disturbed in OSA patients, suggesting that TNF-α could
play a pathophysiologic role in OSA. After this discovery, TNF-α
levels were extensively studied in individuals with OSA (15). In
most of these studies, TNF-α was measured in plasma or serum;
however, in several studies cell-specific levels were also evaluated
(15, 21, 22). In 2003, Dyugovskaya et al. (21) characterized the
cytokine profile of gammadelta T cells in patients with OSA and
control subjects. The major finding regarding OSA gammadelta T
cells was a significant increase in the intracellular content of proin-
flammatory cytokines TNF-α in OSA individuals when compared
with the control group. A year later, it was shown that individ-
uals with moderate-to-severe OSA had spontaneous production
of TNF-α by monocytes and elevated serum levels of TNF-α (23).
Ryan et al. demonstrated an important association between TNF-α
and OSA severity, as serum levels of TNF-α was higher in sub-
jects with OSA than in subjects without OSA (24). Moreover,
other authors have also demonstrated that continuous positive air-
way pressure (CPAP) therapy decreased the TNF-α level in OSA
patients (25). Following this line of reasoning, Dorkova et al. (26)
determined the effects of 8 weeks of CPAP therapy on inflamma-
tion in patients with severe OSA. They provide additional evidence
that OSA caused an increase in TNF-α and also concluded that
compliance with a CPAP regimen can improve the expression of
this inflammatory cytokine. Furthermore, evaluating obese Asian
Indians with OSA, Bhushan et al. (27) clearly demonstrated that
the frequency of the TNF-α (−308A) allele and the serum TNF-α
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level was significantly higher in OSA (27). Despite this evidence
the role of TNF in OSA there is still controversy in the scientific
literature on this aspect. One possible explanation pair these diver-
gences could be related to disease duration, intensity, patient age,
among other factors.
Based on these findings and the fact that TNF-α plays an impor-
tant role in OSA related cardiovascular morbidity, we aimed to
identify other preventive measures, aside from CPAP (successful
treatment with CPAP appears to at least partially abrogate this
risk) (28), that can minimize the inflammatory process in patients
with OSA and thereby prevent possible cardiovascular dysfunction
that may increase the risk of premature death. A possible alter-
native therapy is nutritional immunology, i.e., supplementation
with omega-3 fatty acids (omega-3 FAs). For this proposal, several
lines of evidence should be explored. First, the beneficial effects
of omega-3 FAs in the cardiovascular system have been described
since the late 1970s. It was demonstrated that the low prevalence
of cardiac diseases in Eskimos might be due to their high dietary
intake of omega-3 FAs (29). Currently, several studies have clearly
demonstrated that omega-3 FAs can help prevent coronary heart
disease, reduce arrhythmias and thrombosis, lower plasma triglyc-
eride levels, and reduce blood clotting tendency (30). However,
there is still controversy regarding the real cardiovascular bene-
fits of omega-3 FAs. According to Barrett (31), the majority of
epidemiological studies and interventions demonstrate favorable
cardiovascular outcomes with omega-3 FAs; however, Galli and
Brenna (32) have recently criticized the methodological meta-
analysis and concluded that omega-3 FAs were not effective in
preventing cardiac disorders.
Second, the relationship between omega-3 FAs and OSA is
still rarely evaluated and described in the literature. One of the
most relevant studies on this topic was conducted by Ladesich
et al. (33). In this study, the authors investigated the relation-
ship between omega-3 fatty acid docosahexaenoic acid (DHA)
levels in red blood cells (RBC) and OSA severity in 350 sequential
patients undergoing sleep studies. The authors defined the sever-
ity categories as none/mild, moderate, and severe based on apnea
hypopnea index scores of 0–14, 15–34, and>34, respectively (33).
Briefly, they demonstrated that RBC DHA was inversely related
to OSA severity and that for each 1-SD increase in DHA lev-
els, a patient was approximately 50% less likely to be classified
with severe OSA (33). Thus, the authors concluded that disor-
dered membrane fatty acid patterns may play a causal role in OSA
and that the assessment of RBC DHA levels might help in the diag-
nosis of OSA (33). We fully agree with the authors’ conclusions,
and our research group recently postulated that scientists and clin-
icians should work together in a worldwide network focused on
basic scientific research programs and clinical studies to accurately
establish the use of omega-3 FAs for at risk individuals to prevent
sudden death in OSA patients (34).
Third, it is well documented that chronic inflammation is a
characteristic of severe chronic heart failure (CHF), and inflam-
matory cytokines have been shown to reduce left ventricular (LV)
function, promote LV remodeling, and deteriorate endothelial
function (35–37). Thus, as recent published studies have accurately
demonstrated, supplementation with omega-3 FAs improves sys-
tolic LV function and endothelial function as well as decreases
markers of inflammation in CHF of non-ischemic origin (37) and
other clinical conditions (38, 39). Therefore, it is entirely reason-
able to postulate that omega-3 FA supplementation will be useful
in minimizing the inflammatory cascade and therefore improving
cardiac function in individuals with OSA.
In addition to the above points, omega-3 FAs are well tolerated
with minimal adverse effects (40). As noted, the human body can-
not synthesize omega-3 FAs; therefore, it must be ingested from the
diet. According to the vast literature, seafood (commonly found
in fish and fish oil) is the only food that provides large amounts of
omega-3 FAs (30, 41). The best seafood choices are wild salmon,
anchovies, sardines, trout, herring, and tuna (30, 41). Due to the
importance of the consumption of fish rich in omega-3 FAs, inter-
national guidelines have suggested that the general population
should consume at least 250 mg/day of long-chain omega-3 FAs
or at least two servings/week of oily fish (42). For individuals who
want a contaminant-free diet but would like to enjoy the benefits
of omega-3 FAs, fish oil supplements, or foods such as walnuts or
oils (flax, canola, and soybean) can be consumed (43, 44).
Overall, it is clear that inflammation (especially increased levels
of TNF-α) plays an important role in OSA related cardiovascular
morbidity (45). Due to the beneficial actions of omega-3 FAs for
the cardiovascular system and in minimizing the inflammatory
process, our research group has hypothesized that omega-3 FA
supplementation may be able to reduce cardiac dysfunction and
even the occurrence of premature death in patients with OSA.
We believe that new experimental, epidemiological, and clinical
studies should be evaluated to establish the relationship between
OSA, inflammation, and omega-3 FAs. In the meantime, we should
be optimistic and remember these words by the American writer
and philosopher Robert M. Pirsig: For every fact there is infinity of
hypotheses.
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